{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:04:17Z","timestamp":1790366657039,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1208\/aapsj070102","type":"journal-article","created":{"date-parts":[[2005,9,13]],"date-time":"2005-09-13T16:16:44Z","timestamp":1126628204000},"page":"E6-E13","source":"Crossref","is-referenced-by-count":45,"title":["A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line"],"prefix":"10.1208","volume":"7","author":[{"given":"Olga","family":"Trubetskoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Fei","family":"Yueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Raucy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"71006_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0378-4274(02)00497-6","volume":"140\u2013141","author":"A Bodo","year":"2003","unstructured":"Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B. The role of multidrug transporters in drug availability, metabolism and toxicity.Toxicol Lett; 2003;140\u2013141:133\u2013143.","journal-title":"Toxicol Lett"},{"key":"71006_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/jps.10545","volume":"93","author":"JH Ansede","year":"2004","unstructured":"Ansede JH, Thakker DR. High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism.J Pharm Sci. 2004;93:239\u2013255.","journal-title":"J Pharm Sci."},{"key":"71006_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s002280050638","volume":"55","author":"P Bonnabry","year":"1999","unstructured":"Bonnabry P, Sievering J, Leemann T, Dayer P. Quantitative drug interactions prediction system (Q-DIPS): a computer-based prediction and management support system for drug metabolism interactions.Eur J Clin Pharmacol. 1999;55:341\u2013347.","journal-title":"Eur J Clin Pharmacol"},{"key":"71006_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0006-2952(97)00239-6","volume":"55","author":"LL Moltke von","year":"1998","unstructured":"von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI.In vitro approaches to predicting drug interactionsin vivo.Biochem Pharmacol. 1998;55:113\u2013122.","journal-title":"Biochem Pharmacol"},{"key":"71006_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0300-483X(00)00300-0","volume":"153","author":"JT Moore","year":"2000","unstructured":"Moore JT, Kliewer SA. Use of the nuclear receptor PXR to predict drug interactions.Toxicology. 2000;153:1\u201310.","journal-title":"Toxicology"},{"key":"71006_CR6","first-page":"50","volume":"6","author":"NJ Plant","year":"2003","unstructured":"Plant NJ, Gibson GG. Evaluation of the toxicological relevance of CYP3A4 induction.Curr Opin Drug Discov Devel. 2003;6:50\u201356.","journal-title":"Curr Opin Drug Discov Devel"},{"key":"71006_CR7","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1124\/dmd.30.5.608","volume":"30","author":"PB Desai","year":"2002","unstructured":"Desai PB, Nallani SC, Sane RS, et al. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen.Drug Metab Dispos. 2002;30:608\u2013612.","journal-title":"Drug Metab Dispos"},{"key":"71006_CR8","doi-asserted-by":"publisher","first-page":"7500","DOI":"10.1073\/pnas.130155097","volume":"97","author":"LB Moore","year":"2000","unstructured":"Moore LB, Goodwin B, Jones SA, et al. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor.Proc Natl Acad Sci USA. 2000;97:7500\u20137502.","journal-title":"Proc Natl Acad Sci USA"},{"key":"71006_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1210\/er.2001-0038","volume":"23","author":"SA Kliewer","year":"2002","unstructured":"Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism.Endocr Rev. 2002;23:687\u2013702.","journal-title":"Endocr Rev."},{"key":"71006_CR10","doi-asserted-by":"publisher","first-page":"12208","DOI":"10.1073\/pnas.95.21.12208","volume":"95","author":"G Bertilsson","year":"1998","unstructured":"Bertilsson G, Heidrich J, Svensson K, et al. Identification of a human nuclear receptor defines a new signaling pathway forCYP3A induction.Proc Natl Acad Sci USA. 1998;95:12208\u201312213.","journal-title":"Proc Natl Acad Sci USA"},{"key":"71006_CR11","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1172\/JCI3703","volume":"102","author":"JM Lehmann","year":"1998","unstructured":"Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulateCYP3A4 gene expression and cause drug interactions.J Clin Invest. 1998;102:1016\u20131023.","journal-title":"J Clin Invest."},{"key":"71006_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1124\/dmd.104.001594","volume":"33","author":"MF Yueh","year":"2004","unstructured":"Yueh MF, Kawahara M, Raucy J. High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line.Drug Metab Dispos. 2004;33:38\u201348.","journal-title":"Drug Metab Dispos"},{"key":"71006_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1124\/jpet.102.038653","volume":"303","author":"JL Raucy","year":"2002","unstructured":"Raucy JL, Warfe, L, Yueh M-F, Allen SW. A cell-based reporter gene assay for determining induction of CYP3A4 in a high volume system.J Pharmacol Exp Ther. 2002;303:412\u2013423.","journal-title":"J Pharmacol Exp Ther"},{"key":"71006_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1089\/154065802761001329","volume":"1","author":"BD Marks","year":"2002","unstructured":"Marks BD, Smith RW, Braun HA, et al. A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic Vivid\u00ae P450 substrate.Assay Drug Dev Technol. 2002;1:73\u201381.","journal-title":"Assay Drug Dev Technol"},{"key":"71006_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2165\/00003088-199222010-00005","volume":"22","author":"K Venkatesan","year":"1992","unstructured":"Venkatesan K. Pharmacokinetic drug interactions with rifampicin.Clin Pharmacokinet. 1992;22:47\u201365.","journal-title":"Clin Pharmacokinet"},{"key":"71006_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/ctrv.2001.0228","volume":"27","author":"AF Baker","year":"2001","unstructured":"Baker AF, Dorr RT. Drug interactions with the taxanes: clinical implications.Cancer Treat Rev. 2001;27:221\u2013233.","journal-title":"Cancer Treat Rev"},{"key":"71006_CR17","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1081\/CNV-120025092","volume":"21","author":"M Constantinou","year":"2003","unstructured":"Constantinou M, Tsai JY, Safran H. Paclitaxel and concurrent radiation in upper gastrointestinal cancers.Cancer Invest. 2003;21:887\u2013896.","journal-title":"Cancer Invest"},{"key":"71006_CR18","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1182\/blood-2002-07-2283","volume":"101","author":"HY Li","year":"2003","unstructured":"Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses.Blood. 2003;101:3628\u20133634.","journal-title":"Blood"},{"key":"71006_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1191\/096032799678839699","volume":"18","author":"H Shih","year":"1999","unstructured":"Shih H, Pickwell GV, Guenette DK, Bilir B, Quattrochi LC. Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole.Hum Exp Toxicol. 1999;18:95\u2013105.","journal-title":"Hum Exp Toxicol"},{"key":"71006_CR20","unstructured":"Zlokarnik G, Volak LP, Andrew MM, Tran C, Cleveland T, Makings LR. Novel fluorescent probes detect different types of CYP450-drug interactions in high throughput mode. Gordon Research Conference on Drug Metabolism; July 9\u201314, 2000; Plymouth, NH."},{"key":"71006_CR21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1056-4993(18)30135-4","volume":"9","author":"DA Flockhart","year":"2000","unstructured":"Flockhart DA, Oesterheld JR. Cytochrome P450-mediated drug interactions.Child Adolesc Psychiatr Clin N Am. 2000;9:43\u201376.","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"71006_CR22","first-page":"1644","volume":"29","author":"KE Kenworthy","year":"2001","unstructured":"Kenworthy KE, Clarke SE, Andrews J, Houston JB. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism.Drug Metab. Dispos. 2001;29:1644\u20131651.","journal-title":"Drug Metab. Dispos."},{"key":"71006_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1124\/dmd.32.2.186","volume":"32","author":"L Shen","year":"2004","unstructured":"Shen L, Fitzloff JF, Cook CS. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As.Drug Metab Dispos. 2004;32:186\u2013196. doi:10.1124\/DMD.32.2.186","journal-title":"Drug Metab Dispos"},{"key":"71006_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/med.1016","volume":"21","author":"GN Kumar","year":"2001","unstructured":"Kumar GN, Surapaneni S. Role of drug metabolism in drug discovery and development.Med Res Rev. 2001;21:397\u2013411.","journal-title":"Med Res Rev"},{"key":"71006_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1146\/annurev.pharmtox.40.1.133","volume":"40","author":"RE White","year":"2000","unstructured":"White RE. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery.Annu Rev Pharmacol Toxicol. 2000;40:133\u2013157.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"71006_CR26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/j.1875-9114.1998.tb03830.x","volume":"18","author":"EL Michalets","year":"1998","unstructured":"Michalets EL. Update: clinically significant cytochrome P450 drug interactions.Pharmacotherapy. 1998;18:84\u2013112.","journal-title":"Pharmacotherapy"},{"key":"71006_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","volume":"38","author":"GK Dresser","year":"2000","unstructured":"Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.Clin Pharmacokinet. 2000;38:41\u201357.","journal-title":"Clin Pharmacokinet"},{"key":"71006_CR28","first-page":"1","volume-title":"Drug-Drug Interactions: Analyzing in vitro-in vivo correlations","author":"A Parkinson","year":"1997","unstructured":"Parkinson A, Madan A, Forster J, et al. Enzyme induction: assessing the potential for drug interactions. In: Hori W, ed.Drug-Drug Interactions: Analyzing in vitro-in vivo correlations. Westborough, Massachusetts: International Business Communications, Inc; 1997, 1\u201333."},{"key":"71006_CR29","first-page":"30","volume":"3","author":"GW Caldwell","year":"2000","unstructured":"Caldwell GW. Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetics properties utilizing combined physiochemical, in vitro and in vivo screens.Curr Opin Drug Discov Devel. 2000;3:30\u201341.","journal-title":"Curr Opin Drug Discov Devel"},{"key":"71006_CR30","first-page":"139","volume":"34","author":"U Fuhr","year":"1996","unstructured":"Fuhr U, Weiss M, Kroemer HK, et al. Systematic screening for pharmacokinetic interactions during drug development.J Clin Pharmacol Therap. 1996;34:139\u2013151.","journal-title":"J Clin Pharmacol Therap"},{"key":"71006_CR31","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1016\/0006-2952(94)00312-2","volume":"48","author":"AD Rodrigues","year":"1994","unstructured":"Rodrigues AD. Use ofin vitro human metabolism studies in drug development: An industrial perspective.Biochem Pharmacol. 1994;48:2147\u20132156.","journal-title":"Biochem Pharmacol"},{"key":"71006_CR32","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1124\/jpet.102.033837","volume":"302","author":"JL Raucy","year":"2002","unstructured":"Raucy JL, Mueller L, Duan K, Allen SW, Strom S, Lasker JM. Expression and induction of CYP2C P450 enzymes in primary cultures of human, hepatocytes.J Pharmacol, Exp Ther. 2002;302:475\u2013482.","journal-title":"J Pharmacol, Exp Ther"},{"key":"71006_CR33","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1124\/dmd.31.5.533","volume":"31","author":"JL Raucy","year":"2003","unstructured":"Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products.Drug Metab Dispos. 2003;31:533\u2013539.","journal-title":"Drug Metab Dispos"},{"key":"71006_CR34","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1124\/dmd.30.7.795","volume":"30","author":"G Luo","year":"2002","unstructured":"Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.Drug Metab. Disp. 2002;30:795\u2013804.","journal-title":"Drug Metab. Disp."},{"key":"71006_CR35","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1006\/abio.1999.4460","volume":"278","author":"NJ Plant","year":"2000","unstructured":"Plant NJ, Ogg MS, Crowder M, Gibson GG. Control and statistical analysis ofin vitro reporter gene assays.Anal Biochem. 2000;278:170\u2013174.","journal-title":"Anal Biochem"},{"key":"71006_CR36","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/j.bcp.2003.08.019","volume":"66","author":"BC Spink","year":"2003","unstructured":"Spink BC, Hussain MM, Katz BH, Eisele L, Spink DC. Transient induction of cytochromes P450 1A1 and 1B1 in MCF-7 human breast cancer cells indirubin.Biochem Pharmacol. 2003;66:2313\u20132321.","journal-title":"Biochem Pharmacol"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/aapsj070102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/aapsj070102\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/aapsj070102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/aapsj070102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T12:53:31Z","timestamp":1683204811000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/aapsj070102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["71006"],"URL":"https:\/\/doi.org\/10.1208\/aapsj070102","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}